Phytotherapy in Inflammatory Lung Diseases: An Emerging Therapeutic Interventional Approach

Wadhwa, R; Shukla, SD; Chellappan, DK; Gupta, G; Collet, T; Hansbro, N; Oliver, B; Williams, K; Hansbro, PM; Dua, K; Maurya, PK

Phytotherapy in Inflammatory Lung Diseases: An Emerging Therapeutic Interventional Approach

Wadhwa, R Shukla, SD Chellappan, DK Gupta, G Collet, T Hansbro, N Oliver, B

Williams, K

Hansbro, PM

Dua, K

Maurya, PK

Permalink

Publisher:: Springer
Publication Type:: Chapter
Citation:: Phytochemistry: An in-silico and in-vitro Update, 2019, pp. 331 - 347
Issue Date:: 2019

Closed Access

	Filename	Description	Size
	Wadhwa2019_Chapter_PhytotherapyInInflammatoryLung.pdf	Published version	412.22 kB	Adobe PDF	View/Open
	Wadhwa2019_Chapter_PhytotherapyInInflammatoryLung.pdf	Published version	412.23 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Wadhwa, R	en_US
dc.contributor.author	Shukla, SD	en_US
dc.contributor.author	Chellappan, DK	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Collet, T	en_US
dc.contributor.author	Hansbro, N	en_US
dc.contributor.author	Oliver, B https://orcid.org/0000-0002-7122-9262	en_US
dc.contributor.author	Williams, K https://orcid.org/0000-0002-5094-243X	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.contributor.author	Maurya, PK	en_US
dc.date.issued	2019	en_US
dc.identifier.citation	Phytochemistry: An in-silico and in-vitro Update, 2019, pp. 331 - 347	en_US
dc.identifier.isbn	9789811369193	en_US
dc.identifier.uri	http://hdl.handle.net/10453/138472
dc.description.abstract	Chronic obstructive pulmonary disease (COPD) and asthma are the most common inflammatory respiratory diseases related to an increase in mortality and morbidity. Generally, bronchodilators, ß- agonists, anticholinergics and theophylline used for treatment in these conditions and administered by inhalation for delivery, have localized and systematic effects. The adverse effects are due to pharmacodynamic and pharmacokinetic changes and especially drug-drug and drug-disease interactions. However, phytotherapy is classical and widespread throughout the world for the treatment of ailments. This chapter highlights cellular and molecular mediators involved in COPD and asthma, the shortcomings of current therapies and the emerging need of phytomedicines. Phytomedicine supports respiratory physiology, bronchial action and possesses antioxidants to maintain homeostasis.	en_US
dc.publisher	Springer	en_US
dc.relation	http://purl.org/au-research/grants/nhmrc/APP1026880
dc.relation	http://purl.org/au-research/grants/nhmrc/APP1110368
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation.ispartof	Phytochemistry: An in-silico and in-vitro Update	en_US
dc.relation.isbasedon	10.1007/978-981-13-6920-9_18	en_US
dc.title	Phytotherapy in Inflammatory Lung Diseases: An Emerging Therapeutic Interventional Approach	en_US
dc.type	Chapter
utslib.location	Singapore	en_US
utslib.for	1102 Cardiorespiratory Medicine and Haematology	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHSP - Health Services and Practice
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Students
utslib.copyright.status	closed_access
pubs.consider-herdc	false	en_US
pubs.place-of-publication	Singapore	en_US
pubs.publication-status	Published	en_US

Abstract:

Chronic obstructive pulmonary disease (COPD) and asthma are the most common inflammatory respiratory diseases related to an increase in mortality and morbidity. Generally, bronchodilators, ß- agonists, anticholinergics and theophylline used for treatment in these conditions and administered by inhalation for delivery, have localized and systematic effects. The adverse effects are due to pharmacodynamic and pharmacokinetic changes and especially drug-drug and drug-disease interactions. However, phytotherapy is classical and widespread throughout the world for the treatment of ailments. This chapter highlights cellular and molecular mediators involved in COPD and asthma, the shortcomings of current therapies and the emerging need of phytomedicines. Phytomedicine supports respiratory physiology, bronchial action and possesses antioxidants to maintain homeostasis.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/138472